Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stockZydus Wellness Ltd (ZYDUSWELL) is currently trading at 513.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Zydus Wellness Limited is a prominent Indian consumer wellness company specializing in health and wellness products. Its portfolio includes well-known brands like Sugar Free, Complan, Everyuth, and Glucon-D. The company continues to show robust international growth, with significant expansion in Europe through its acquisition of Comfort Click. This strategic acquisition has allowed Zydus to access new wellness markets across Europe. Financially, Zydus Wellness has shown impressive growth, with net sales for Q3 FY26 increasing by 113.7% year-on-year. The company's food and nutrition segment thrived with a 134% increase, although personal care slightly dipped. Zydus Wellness has demonstrated strong innovation, with new product developments in both domestic and international markets, such as Nutrarlite's new mayonnaise variants and Comfort Click’s diverse gummy supplements. Despite these growth areas, the company faced a net loss this quarter, greatly influenced by acquisition-related costs, which management assures will be cash EPS accretive in the medium to long term.
Over the past 52 weeks, Zydus Wellness Ltd has traded between a low of ₹321.24 and a high of ₹552.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Zydus Wellness Ltd has a market capitalization of approximately 16,200.74. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Zydus Wellness Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 82.15 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 16,200.74 Cr, Zydus Wellness Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Zydus Wellness Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Zydus Wellness Ltd is 82.15. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue rose 16.2% to ₹7,587 crore, EBITDA increased 20.2% to ₹2,554 crore, and EBITDA margin expanded to 33.7% from 32.6%.
The stock surged amid heavy volumes as investors focused on expectations of volume-led Q4 growth, strong Q3FY26 YoY performance, and Motilal Oswal’s ‘Buy’ initiation with a ₹575 target.
Sales rose 62.10% year-on-year to ₹1,476.1 crore, while net profit declined 5.76% to ₹162.0 crore.
Zydus Wellness Ltd. is scheduled to report upcoming earnings on 3 February 2026.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Zydus Wellness Limited is a prominent Indian consumer wellness company specializing in health and wellness products. Its portfolio includes well-known brands like Sugar Free, Complan, Everyuth, and Glucon-D.
The company continues to show robust international growth, with significant expansion in Europe through its acquisition of Comfort Click. This strategic acquisition has allowed Zydus to access new wellness markets across Europe.
Financially, Zydus Wellness has shown impressive growth, with net sales for Q3 FY26 increasing by 113.7% year-on-year. The company's food and nutrition segment thrived with a 134% increase, although personal care slightly dipped.
Zydus Wellness has demonstrated strong innovation, with new product developments in both domestic and international markets, such as Nutrarlite's new mayonnaise variants and Comfort Click’s diverse gummy supplements.
Despite these growth areas, the company faced a net loss this quarter, greatly influenced by acquisition-related costs, which management assures will be cash EPS accretive in the medium to long term.
Food Products
Packaged Foods
16,346 Cr
Low Risk
82.9
44.5
1.5
2.8
552.40
321.24
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
2
Neutral
8
Bullish
4
Bearish
3
Neutral
8
Bullish
35
Bearish
1
Neutral
0
Bullish
31
Audited financial results
Zydus Wellness released a newspaper extract of audited consolidated results for Q4 and FY ended Mar 31, 2026: FY total income ₹39,674m, FY net profit ₹1,972m (down from ₹3,469m YoY); Q4 total income ₹14,859m, Q4 net profit ₹1,620m.
Investor Call Recording
Zydus Wellness posted the audio recording of its investor call on the audited financial results for the quarter and fiscal year ended March 31, 2026, available on the company website (link provided).
Dividend & Board Appointment
Zydus Wellness recommended a final dividend of ₹1.20/share (60%) for FY26; record date July 17, 2026 and payment from Aug 7, 2026 pending AGM approval on Aug 4, 2026; appointed Apurva S. Diwanji as Additional Independent Director (May 18, 2026–May 17, 2031).
Dividend & Director Appointment
Zydus Wellness' Board recommended a final dividend of ₹1.20/share for FY26, fixed record date July 17, 2026 and payment from Aug 7, 2026 (subject to AGM approval); 32nd AGM on Aug 4, 2026; appointed Apurva S. Diwanji as Additional Independent Director (May 18, 2026–May 17, 2031) subject to member approval.
Financial Results
Zydus Wellness reported Q4 consolidated net sales of Rs 14,761m (+62.1% y/y) and FY26 net sales of Rs 39,400m (+46.4%); EBITDA Rs 5,097m (+34.2% y/y) and FY PAT Rs 1,972m, with several brand launches and category gains.
Financial Results
Zydus Wellness reports Q4 FY26 consolidated net sales of Rs 14,761m (+62.1% YoY) and FY26 net sales of Rs 39,400m (+46.4%); EBITDA Rs 5,097m (+34.2% YoY) and FY26 PAT Rs 1,972m; brand shares expanded across portfolios.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
664.30 | 17,000 Cr | 68.94 | 11.34 | 0.15 | 14.21 | 16.12 | 10.88 | ||
498.55 | 16,201 Cr | 82.15 | 2.78 | 0.24 | 3.98 | 4.07 | 1.91 | ||
1523.10 | 10,659 Cr | 8.58 | 1.51 | 0.00 | 17.65 | 40.07 | 17.19 | ||
192.80 | 5,659 Cr | 40.49 | 4.66 | 0.65 | 11.21 | 13.73 | 8.37 | ||
290.90 | 3,661 Cr | 49.71 | 7.65 | 0.34 | 9.30 | 10.51 | 10.30 | ||
188.80 | 2,943 Cr | 32.73 | 5.15 | 0.45 | 15.72 | 19.58 | 11.92 | ||
944.20 | 2,523 Cr | 128.02 | 3.73 | 0.19 | 3.00 | 1.06 | 2.16 | ||
| Median: 7 Co. | — | 498.55 | 5,659 Cr | 49.71 | 4.66 | 0.24 | 11.21 | 13.73 | 10.30 |
